CN116178670B - Polyurethane composite material for medical dressing foam and preparation method thereof - Google Patents
Polyurethane composite material for medical dressing foam and preparation method thereof Download PDFInfo
- Publication number
- CN116178670B CN116178670B CN202310473192.7A CN202310473192A CN116178670B CN 116178670 B CN116178670 B CN 116178670B CN 202310473192 A CN202310473192 A CN 202310473192A CN 116178670 B CN116178670 B CN 116178670B
- Authority
- CN
- China
- Prior art keywords
- component
- agent
- polyether
- parts
- medical dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/30—Low-molecular-weight compounds
- C08G18/32—Polyhydroxy compounds; Polyamines; Hydroxyamines
- C08G18/3271—Hydroxyamines
- C08G18/3275—Hydroxyamines containing two hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/30—Low-molecular-weight compounds
- C08G18/32—Polyhydroxy compounds; Polyamines; Hydroxyamines
- C08G18/3271—Hydroxyamines
- C08G18/3278—Hydroxyamines containing at least three hydroxy groups
- C08G18/3281—Hydroxyamines containing at least three hydroxy groups containing three hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4804—Two or more polyethers of different physical or chemical nature
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4833—Polyethers containing oxyethylene units
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/50—Polyethers having heteroatoms other than oxygen
- C08G18/5072—Polyethers having heteroatoms other than oxygen containing sulfur
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/65—Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen
- C08G18/66—Compounds of groups C08G18/42, C08G18/48, or C08G18/52
- C08G18/6666—Compounds of group C08G18/48 or C08G18/52
- C08G18/667—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38
- C08G18/6681—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38 with compounds of group C08G18/32 or C08G18/3271 and/or polyamines of C08G18/38
- C08G18/6688—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38 with compounds of group C08G18/32 or C08G18/3271 and/or polyamines of C08G18/38 with compounds of group C08G18/3271
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/74—Polyisocyanates or polyisothiocyanates cyclic
- C08G18/76—Polyisocyanates or polyisothiocyanates cyclic aromatic
- C08G18/7614—Polyisocyanates or polyisothiocyanates cyclic aromatic containing only one aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2101/00—Manufacture of cellular products
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2110/00—Foam properties
- C08G2110/0083—Foam properties prepared using water as the sole blowing agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention belongs to the technical field of medical polyurethane, and particularly relates to a polyurethane composite material for medical dressing foam and a preparation method thereof. The polyurethane composite material for medical dressing foam is prepared from a component A and a component B according to the mass ratio of 100 (55-60); wherein, the A component is as follows by weight portion: 85-90 parts of foaming agent, 0.5-1 part of antibacterial agent, 2-5 parts of cross-linking agent, 4-8 parts of emulsifying wax and 2-5 parts of pore opening agent; the component B is as follows: 50-60 parts of hydrophilic polyether polyol A, 3-8 parts of chain extender polyether B and 35-45 parts of toluene diisocyanate. The invention has the advantages of low density, good rebound resilience in water, good water absorption and water retention, excellent mechanical property, good durability, no catalyst, safety and environmental protection. The invention also provides a scientific and reasonable preparation method.
Description
Technical Field
The invention belongs to the technical field of medical polyurethane, and particularly relates to a polyurethane composite material for medical dressing foam and a preparation method thereof.
Background
The medical dressing is mainly used for applying, treating, wrapping and the like of wounds, and is a very important medical material. The wound can be protected, secondary injury and bacterial infection of the wound are avoided, a dry and breathable environment can be provided, and wound healing is accelerated. Traditional dressing mainly adopts cotton yarn preparation, but cotton yarn class medical dressing only can play the guard action, and aseptic, the desiccation condition effect that needs to the wound is limited, pastes the wound department simultaneously easily, causes to draw and tear and bring the secondary injury to the wound. With the intensive research of pathophysiology of wound healing process, medical technology is advancing, the use demands of patients are continuously improved, the traditional dressing can not meet market demands more and more, and development of novel medical dressing is urgently needed.
The hydrophilic polyurethane foam has excellent absorption performance, biocompatibility and anticoagulation performance, and the toxicity test meets the medical requirements, has no distortion effect and no anaphylactic reaction, has excellent toughness and elasticity, and has good processing performance and various processing modes, so that the hydrophilic polyurethane material is successfully applied to the field of medical dressing.
Chinese patent No. 113289045A (publication No. 2021.8.24) uses polyether polyol, polyisocyanate, chain extender, foam stabilizer, foaming agent, organotin catalyst, amine catalyst and hydrophilic modifier to obtain medical sponge dressing. The method utilizes the combined action of the hydrophilia of the difunctional carboxyl and the hydroxyl to improve the water absorption rate of the foam, so that the water absorption rate of the polyurethane foam reaches more than 30g/g, but the used organotin catalyst has strong biotoxicity, and the amine catalyst has corrosiveness to skin and is not beneficial to wound healing.
Disclosure of Invention
In order to solve the technical problems, the polyurethane composite material for the medical dressing foam is low in density, good in rebound resilience in water, good in water absorption and water retention, excellent in mechanical property, good in durability, free of catalyst, safe and environment-friendly. The invention also provides a scientific and reasonable preparation method.
The polyurethane composite material for medical dressing foam is prepared from a component A and a component B according to the mass ratio of 100 (55-60);
wherein, the A component is as follows by weight portion:
85-90% of a foaming agent,
0.5 to 1 percent of antibacterial agent,
2-5% of a cross-linking agent,
4-8% of emulsifying wax,
2-5 parts of a pore opening agent;
the component B is as follows:
50-60% of hydrophilic polyether polyol A,
3-8 parts of chain extender polyether B,
35-45 parts of toluene diisocyanate.
Wherein the hydrophilic polyether polyol A is EO/PO copolymerized polyether, and the chain extender polyether B is modified dimethylolbutyric acid.
The hydrophilic polyether polyol A has a hydroxyl value of 100-120 mgKOH/g and a number average molecular weight of 1000-1200, is prepared by ring-opening polymerization of sodium isethionate and glycerin serving as composite initiators, KOH serving as a catalyst, PO and EO, wherein EO accounts for more than 75% of the total mass of the PO and EO.
The preparation method of the hydrophilic polyether polyol A comprises the following steps:
(1) Adding sodium isethionate, glycerol and KOH into a high-pressure reaction kettle, performing nitrogen substitution for 2 times, starting vacuumizing to-0.95 to-0.1 MPa, maintaining vacuum, heating to 180-190 ℃, preserving heat for 2-2.5 h, then cooling to 110 ℃, sequentially and continuously introducing PO and EO or continuously introducing a mixture of PO and EO, controlling the pressure in the kettle to be less than 0.5MPa, preserving heat at 120 ℃ after the kettle is completely filled until negative pressure appears, and cooling and discharging to obtain crude ether;
(2) Pouring the crude ether into a container with a stirrer and a thermometer, adding distilled water, heating to 80-90 ℃, and stirring for 1-2 h; adding phosphoric acid, stirring for 1-2 hours, adding a refining agent magnesium silicate, and stirring for 1-2 hours; and vacuumizing and dehydrating at 115-120 ℃ until the water content is less than or equal to 0.05%, and filtering to remove the refined agent to obtain the hydrophilic polyether polyol A.
The functionality of the chain extender polyether B is 2, the hydroxyl value is 265-284 mg KOH/g, dimethylolbutyric acid is used as an initiator, KOH is used as a catalyst, and ring-opening polymerization is carried out on the chain extender polyether B and EO;
the preparation method of the chain extender polyether B comprises the following steps:
(1) Adding dimethylolbutyric acid and KOH into a high-pressure reaction kettle, performing nitrogen substitution for 2 times, starting vacuumizing to-0.95 to-0.1 MPa, maintaining vacuum, heating to 115-120 ℃, preserving heat for 2-2.5 h, then cooling to 110 ℃, continuously introducing EO, controlling the pressure in the kettle to be less than 0.5MPa, preserving heat at 120 ℃ after the kettle is completely filled, until negative pressure appears, and cooling and discharging to obtain crude ether;
(2) Pouring the crude ether into a container with a stirrer and a thermometer, adding distilled water, heating to 80-90 ℃, and stirring for 1-2 h; adding phosphoric acid, stirring for 1-2 hours, adding a refining agent magnesium silicate, and stirring for 1-2 hours; and vacuumizing and dehydrating at 115-120 ℃ until the water content is less than or equal to 0.05%, and filtering to remove the refined agent to obtain the chain extender polyether B.
The foaming agent is water.
The antibacterial agent is lysozyme.
The cross-linking agent is one or two of diethanolamine and triethanolamine.
The emulsifying wax is a nonionic emulsifying matrix and can help color fixation and coloring of products, preferably 1000NI of Basoff Limited of Germany.
The pore-forming agent is a nonionic low-foaming surfactant, a polyether EO/PO/EO block copolymer, and has a number average molecular weight of 8000-10000, preferably PE6800 of Basoff Co., germany.
Toluene diisocyanate was T-80.
The preparation method of the polyurethane composite material for medical dressing foam comprises the following steps:
and (3) preparing a component A: adding a foaming agent, an antibacterial agent, a cross-linking agent, emulsifying wax and a pore opening agent into a reaction kettle, stirring, and stirring for 30-40 min at a rotating speed of 30-40 r/min at room temperature to obtain a component A product;
and (2) preparing a component B: placing the hydrophilic polyether polyol A and the chain extender polyether B in a reaction kettle, heating to 120-130 ℃, dehydrating in vacuum for 1-1.5 h, then cooling to 40-45 ℃, adding toluene diisocyanate, heating to 80-85 ℃, reacting for 3-3.5 h under heat preservation, sampling and detecting that the mass percentage of-NCO reaches 10% -16%, cooling, discharging, and sealing and preserving.
Compared with the prior art, the invention has the beneficial effects that:
1. the hydrophilic polyether polyol A and the chain extender polyether B are adopted to synthesize the hydrophilic polyurethane prepolymer, and the synergistic hydrophilic effect of ether bond, carboxyl and sulfonate is utilized to prepare the medical dressing with low density, good rebound resilience in water, good water absorption and water retention, excellent mechanical property and good durability;
2. the preparation method has simple process and high production efficiency;
3. the invention does not adopt any catalyst, and is safe and environment-friendly.
Detailed Description
The technical scheme of the present invention will be clearly and completely described in the following examples.
All materials used in the examples are commercially available, except as specified.
Example 1
The polyurethane composite material for medical dressing foam is prepared from a component A and a component B;
wherein, the A component is as follows by weight portion:
the water 85 is provided with a water-absorbing agent,
the lysozyme is 1-part of the lysozyme,
2.5 parts of diethanolamine, wherein the ethanol is added,
2.5 parts of triethanolamine, wherein the triethanolamine is selected from the group consisting of ethanol, water, and mixtures thereof,
1000NI 4，
PE6800 5；
the component B is as follows:
a hydrophilic polyether polyol a 60,
the chain extender polyether B3 is used for preparing the polymer,
T-80 45。
the preparation method of the hydrophilic polyether polyol A comprises the following steps:
(1) Adding 1mol of sodium isethionate, 1.5mol of glycerol and 0.1kg of KOH into a high-pressure reaction kettle, performing nitrogen substitution for 2 times, starting vacuumizing to-0.95 MPa, maintaining vacuum, heating to 180 ℃, preserving heat for 2 hours, then cooling to 110 ℃, sequentially and continuously introducing 1mol of PO and 16mol of EO, controlling the pressure in the kettle to be 0.4MPa, preserving heat at 120 ℃ after the kettle is completely filled, cooling and discharging until negative pressure appears, and obtaining crude ether;
(2) Pouring the crude ether into a container with a stirrer and a thermometer, adding distilled water, heating to 80 ℃, and stirring for 2h; adding 0.04kg of phosphoric acid, stirring for 1h, adding 1kg of refining agent magnesium silicate, and stirring for 2h; vacuum dewatering at 120deg.C until water content is 0.05%, filtering to remove refined agent to obtain hydrophilic polyether polyol A with hydroxyl value of 117.2mgKOH/g and number average molecular weight of 1045.
The preparation method of the chain extender polyether B comprises the following steps:
(1) Adding 1mol of dimethylolbutyric acid and 0.04kg of KOH into a high-pressure reaction kettle, carrying out nitrogen substitution for 2 times, starting vacuumizing to-0.1 MPa, keeping vacuum, heating to 115 ℃, preserving heat for 2.5 hours, then cooling to 110 ℃, continuously introducing 6mol of EO, controlling the pressure in the kettle to be 0.45MPa, preserving heat at 120 ℃ after the kettle is completely filled, cooling and discharging until negative pressure appears, and obtaining crude ether;
(2) Pouring the crude ether into a container with a stirrer and a thermometer, adding distilled water, heating to 80 ℃, and stirring for 2h; adding 0.016kg of phosphoric acid, stirring for 2h, adding 0.8kg of refining agent magnesium silicate, and stirring for 1h; vacuum dehydration is carried out at 115 ℃ until the water content is 0.045%, and the refined agent is removed by filtration, thus obtaining the chain extender polyether B with the functionality of 2 and the hydroxyl value of 272.4mgKOH/g.
The preparation method of the polyurethane composite material for medical dressing foam comprises the following steps:
and (3) preparing a component A: adding water, lysozyme, diethanolamine, triethanolamine, 1000NI and PE6800 into a reaction kettle, stirring, and stirring for 40min at a rotating speed of 30r/min at room temperature to obtain a component A product;
and (2) preparing a component B: placing hydrophilic polyether polyol A and chain extender polyether B in a reaction kettle, heating to 120 ℃ for vacuum dehydration for 1.5h, then cooling to 40 ℃, adding T-80, heating to 80 ℃ for heat preservation reaction for 3.5h, sampling and detecting that the mass percentage of-NCO reaches 15.8%, cooling and discharging, and sealing and preserving.
When the medical dressing foam is used, a layer of release agent is firstly wiped in the mold, the component A and the component B are quickly and uniformly mixed according to the weight ratio of 100:55 at room temperature, then the mixture is poured into the mold, and the mold is opened after 4min, so that the medical dressing foam is obtained.
Example 2
The polyurethane composite material for medical dressing foam is prepared from a component A and a component B;
wherein, the A component is as follows by weight portion:
the water 90 is provided with a water-absorbing agent,
0.5 percent of lysozyme, the total amount of the components,
the aqueous solution of triethanolamine 2 is used for preparing the aqueous solution,
1000NI 5.5，
PE6800 2；
the component B is as follows:
the hydrophilic polyether polyol a 57,
the chain extender polyether B8 is used for preparing the polymer,
T-80 35。
the preparation method of the hydrophilic polyether polyol A comprises the following steps:
(1) Adding 1mol of sodium isethionate, 1.4mol of glycerol and 0.15kg of KOH into a high-pressure reaction kettle, performing nitrogen substitution for 2 times, starting vacuumizing to-0.1 MPa, maintaining vacuum, heating to 190 ℃, preserving heat for 2.5 hours, then cooling to 110 ℃, continuously introducing a mixture of 1.5mol of PO and 16.5mol of EO, controlling the pressure in the kettle to be 0.35MPa, preserving heat at 120 ℃ after the kettle is completely filled until negative pressure appears, and cooling and discharging to obtain crude ether;
(2) Pouring the crude ether into a container with a stirrer and a thermometer, adding distilled water, heating to 90 ℃, and stirring for 1h; adding 0.055kg of phosphoric acid, stirring for 2 hours, then adding 1.2kg of refining agent magnesium silicate, and stirring for 1 hour; vacuum dewatering at 120deg.C until water content is 0.035%, filtering to remove refined agent to obtain hydrophilic polyether polyol A with hydroxyl value of 114.7mgKOH/g and number average molecular weight of 1060.
The preparation method of the chain extender polyether B comprises the following steps:
(1) Adding 1mol of dimethylolbutyric acid and 0.035kg of KOH into a high-pressure reaction kettle, carrying out nitrogen substitution for 2 times, then starting vacuumizing to-0.98 MPa, keeping vacuum, heating to 120 ℃, carrying out heat preservation for 2 hours, then cooling to 110 ℃, continuously introducing 6.2mol of EO, controlling the pressure in the kettle to be 0.4MPa, carrying out heat preservation at 120 ℃ after the completion of the introduction until negative pressure appears, and cooling and discharging to obtain crude ether;
(2) Pouring the crude ether into a container with a stirrer and a thermometer, adding distilled water, heating to 90 ℃, and stirring for 1h; adding 0.012kg of phosphoric acid, stirring for 1h, adding 0.7kg of refining agent magnesium silicate, and stirring for 2h; vacuum dehydration is carried out at 115 ℃ until the moisture content is 0.04%, and the refined agent is removed by filtration, thus obtaining the chain extender polyether B with the functionality of 2 and the hydroxyl value of 266.4mgKOH/g.
The preparation method of the polyurethane composite material for medical dressing foam comprises the following steps:
and (3) preparing a component A: adding water, lysozyme, triethanolamine, 1000NI and PE6800 into a reaction kettle, stirring, and stirring for 40min at a rotation speed of 40r/min at room temperature to obtain a component A product;
and (2) preparing a component B: placing hydrophilic polyether polyol A and chain extender polyether B in a reaction kettle, heating to 130 ℃ for vacuum dehydration for 1h, then cooling to 45 ℃, adding T-80, heating to 85 ℃ for heat preservation reaction for 3h, sampling and detecting that the mass percentage of-NCO reaches 10.2%, cooling and discharging, and sealing for preservation.
When the medical dressing foam is used, a layer of release agent is firstly wiped in the mold, the component A and the component B are quickly and uniformly mixed according to the weight ratio of 100:60 at room temperature, then the mixture is poured into the mold, and the mold is opened after 4min, so that the medical dressing foam is obtained.
Example 3
The polyurethane composite material for medical dressing foam is prepared from a component A and a component B;
wherein, the A component is as follows by weight portion:
the water content of the water is 85.4,
0.6 part of lysozyme, the total amount of the components,
a diethanolamine salt of the acid, 3,
1000NI 8，
PE6800 3；
the component B is as follows:
a hydrophilic polyether polyol A50,
the chain extender polyether B7 is used for preparing the polymer,
T-80 43。
the preparation method of the hydrophilic polyether polyol A comprises the following steps:
(1) Adding 1mol of sodium isethionate, 1.3mol of glycerol and 0.18kg of KOH into a high-pressure reaction kettle, performing nitrogen substitution for 2 times, starting vacuumizing to-0.98 MPa, maintaining vacuum, heating to 185 ℃, preserving heat for 2.2 hours, then cooling to 110 ℃, sequentially and continuously introducing 2mol of PO and 18mol of EO, controlling the pressure in the kettle to be 0.3MPa, preserving heat at 120 ℃ after the kettle is completely filled, cooling and discharging until negative pressure appears, and obtaining crude ether;
(2) Pouring the crude ether into a container with a stirrer and a thermometer, adding distilled water, heating to 85 ℃, and stirring for 1.5h; adding 0.065kg of phosphoric acid, stirring for 1.5h, adding 1.5kg of refining agent magnesium silicate, and stirring for 1.5h; vacuum dewatering at 120deg.C until water content is 0.03%, filtering to remove refined agent to obtain hydrophilic polyether polyol A with hydroxyl value of 101.6mgKOH/g and number average molecular weight of 1175.
The preparation method of the chain extender polyether B comprises the following steps:
(1) Adding 1mol of dimethylolbutyric acid and 0.03kg of KOH into a high-pressure reaction kettle, carrying out nitrogen substitution for 2 times, starting vacuumizing to-0.95 MPa, maintaining vacuum, heating to 118 ℃, preserving heat for 1.5 hours, then cooling to 110 ℃, continuously introducing 5.7mol of EO, controlling the pressure in the kettle to be 0.3MPa, preserving heat at 120 ℃ after the kettle is completely filled, cooling and discharging until negative pressure appears, and obtaining crude ether;
(2) Pouring the crude ether into a container with a stirrer and a thermometer, adding distilled water, heating to 85 ℃, and stirring for 1.5h; adding 0.012kg of phosphoric acid, stirring for 1.5h, adding 0.9kg of refining agent magnesium silicate, and stirring for 1.5h; vacuum dehydration is carried out at 115 ℃ until the water content is 0.035%, and the refined agent is removed by filtration, thus obtaining the chain extender polyether B with the functionality of 2 and the hydroxyl value of 280.8mgKOH/g.
The preparation method of the polyurethane composite material for medical dressing foam comprises the following steps:
and (3) preparing a component A: 85.4kg of water, 0.6kg of lysozyme, 3kg of diethanolamine, 8kg of 1000NI and 3kg of PE6800 are put into a reaction kettle to be stirred, and the mixture is stirred for 35min at the room temperature with the rotating speed of 35 r/min, so that a component A product is obtained;
and (2) preparing a component B: placing 50kg of hydrophilic polyether polyol A and 7kg of chain extender polyether B into a reaction kettle, heating to 125 ℃ for vacuum dehydration for 1.2h, then cooling to 43 ℃, adding 43kg of 10T-80, heating to 83 ℃ for heat preservation reaction for 3.2h, sampling and detecting that the mass percentage of-NCO reaches 15.4%, cooling and discharging, and sealing and preserving.
When the medical dressing foam is used, a layer of release agent is firstly wiped in the mold, the component A and the component B are quickly and uniformly mixed according to the weight ratio of 100:58 at room temperature, then the mixture is poured into the mold, and the mold is opened after 4 minutes, so that the medical dressing foam is obtained.
Comparative example 1
This comparative example 1 differs from example 3 in that diethanolamine in the a-component was replaced with ethylene glycol of the same quality, and was the same as example 3.
Comparative example 2
This comparative example 2 is different from example 3 in that the pore-forming agent PE6800 in the A-component was replaced with an equivalent quality pore-forming agent INOV-S25K (New materials Co., ltd.) in the same manner as in example 3.
Comparative example 3
This comparative example 3 differs from example 3 in that the hydrophilic polyether polyol a in the B component was replaced with a hydrophilic polyether polyol C of the same quality (the only difference from the hydrophilic polyether polyol a is that ethylene glycol and glycerin are used as composite initiators in a molar ratio of 20:3, and the rest of the synthesis methods and indices are the same as those of the hydrophilic polyether polyol a), all of which are the same as those of example 3.
Comparative example 4
This comparative example 4 differs from example 3 in that the chain extender polyether B in the B component was replaced with polyethylene glycol 400 of equivalent mass (commercially available), all in the same way as example 3.
Comparative example 5
This comparative example 5 differs from example 3 in that the chain extender polyether B in the B component was replaced with dimethylolbutyric acid of the same quality, all as in example 3.
Comparative example 6
This comparative example 6 is different from example 3 except that T-80 in the B component is replaced with T-65 of the same mass as in example 3.
Comparative example 7
This comparative example 7 differs from example 3 in that T-80 in the B component was replaced with MDI-50 of the same mass, all as in example 3.
Performance testing
The medical dressing foams prepared in examples 1 to 3 and comparative examples 1 to 7 were subjected to performance test, and the test results are shown in table 1.
Wherein, the core density is detected according to GB/T6343-1995 standard; elongation at break and tensile strength are detected according to GB/T6344-1996 standard; the tearing strength is detected according to GB/T10808-2006 standard; the method for testing rebound in water comprises the following steps: placing medical dressing foam into water, taking out after 20min, forcibly extruding out water, and recording the time required for restoring the product; the water absorption and water retention were measured according to the following methods, respectively;
water absorption rate: 50mm by 50mm medical dressing foam, measured in mass m 1 Then soaking in water and repeatedly squeezing for 30 times, and measuring the mass m after soaking in water for 1h 2 The water absorption was calculated by the following formula:
，
water retention rate: 50mm×50mm medical dressing foam, measured in mass m 1 Soaking in water, repeatedly squeezing for 30 times, standing for 1 hr, and measuring foam mass as m after 1 hr 3 The water absorption was calculated by the following formula.
。
Table 1 performance test tables for examples 1 to 3 and comparative examples 1 to 7
As can be seen from Table 1, the medical dressing foams of examples 1-3 of the present invention have not only good rebound resilience performance in water and good hydrophilicity, but also good water absorption and water retention properties and excellent mechanical properties. As can be seen from comparison of example 3 and comparative examples 1-7, the mechanical properties, rebound resilience in water, water absorption and water retention of the product are obviously improved by using the cross-linking agent, the hydrophilic polyether polyol A, the chain extender polyether B, the pore opening agent PE6800 and T-80 and simultaneously utilizing the synergistic effect of carboxyl, ether bond and sulfonate.
Claims (4)
1. The polyurethane composite material for the medical dressing foam is characterized by being prepared from a component A and a component B according to the mass ratio of 100 (55-60);
wherein, the A component is as follows by weight portion:
85-90% of a foaming agent,
0.5 to 1 percent of antibacterial agent,
2-5% of a cross-linking agent,
4-8% of emulsifying wax,
2-5 parts of a pore opening agent;
the component B is as follows:
50-60% of hydrophilic polyether polyol A,
3-8 parts of chain extender polyether B,
35-45 parts of toluene diisocyanate;
wherein the hydrophilic polyether polyol A is EO/PO copolymerized polyether, and the chain extender polyether B is modified dimethylolbutyric acid;
the hydrophilic polyether polyol A has a hydroxyl value of 100-120 mgKOH/g and a number average molecular weight of 1000-1200, is prepared by ring-opening polymerization of sodium isethionate and glycerin serving as composite initiators, KOH serving as a catalyst, PO and EO, wherein EO accounts for more than 75% of the total mass of the PO and EO;
the functionality of the chain extender polyether B is 2, the hydroxyl value is 265-284 mg KOH/g, dimethylolbutyric acid is used as an initiator, KOH is used as a catalyst, and ring-opening polymerization is carried out on the chain extender polyether B and EO;
the foaming agent is water;
the cross-linking agent is one or two of diethanolamine and triethanolamine;
the pore opening agent is a nonionic low-foam surfactant, and the polyether EO/PO/EO segmented copolymer has a number average molecular weight of 8000-10000;
toluene diisocyanate was T-80.
2. The polyurethane foam composition for medical dressing according to claim 1, wherein the antibacterial agent is lysozyme.
3. The polyurethane composition for medical dressing foam according to claim 1, wherein the emulsifying wax is a nonionic emulsifying matrix.
4. A method for preparing the polyurethane composite material for medical dressing foam according to any one of claims 1 to 3, which is characterized by comprising the following steps:
and (3) preparing a component A: adding a foaming agent, an antibacterial agent, a cross-linking agent, emulsifying wax and a pore opening agent into a reaction kettle, stirring, and stirring for 30-40 min at a rotating speed of 30-40 r/min at room temperature to obtain a component A product;
and (2) preparing a component B: placing the hydrophilic polyether polyol A and the chain extender polyether B in a reaction kettle, heating to 120-130 ℃, dehydrating in vacuum for 1-1.5 h, then cooling to 40-45 ℃, adding toluene diisocyanate, heating to 80-85 ℃, reacting for 3-3.5 h under heat preservation, sampling and detecting that the mass percentage of-NCO reaches 10% -16%, cooling, discharging, and sealing for preservation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310473192.7A CN116178670B (en) | 2023-04-28 | 2023-04-28 | Polyurethane composite material for medical dressing foam and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310473192.7A CN116178670B (en) | 2023-04-28 | 2023-04-28 | Polyurethane composite material for medical dressing foam and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116178670A CN116178670A (en) | 2023-05-30 |
| CN116178670B true CN116178670B (en) | 2023-07-28 |
Family
ID=86446619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310473192.7A Active CN116178670B (en) | 2023-04-28 | 2023-04-28 | Polyurethane composite material for medical dressing foam and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116178670B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2158924A1 (en) * | 2008-08-27 | 2010-03-03 | Bayer MaterialScience AG | Method for producing formed polyurethane foam wound dressing |
| CN105153393A (en) * | 2015-08-04 | 2015-12-16 | 李明莹 | Hydrophilic and biological safe polymer foam, and preparation method and application of polymer foam |
| CN105440240A (en) * | 2015-12-04 | 2016-03-30 | 上海华峰材料科技研究院（有限合伙） | Continuous production method for preparing waterborne polyurethane ionomer and dispersoid of waterborne polyurethane ionomer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9102660D0 (en) * | 1991-02-07 | 1991-03-27 | Ultra Lab Ltd | Wound dressing materials |
| KR100340981B1 (en) * | 1999-07-01 | 2002-06-20 | 박명환 | Hydrophilic Polyurethane Foam Dressing and Method of Making the Same |
| CN1202785C (en) * | 2003-06-24 | 2005-05-25 | 四川大学 | Hydrophilic trauma dressing made from polyurethane and its preparation method |
| EP2072063A1 (en) * | 2007-12-22 | 2009-06-24 | Bayer Innovation GmbH | Infection-resistant cellular hydrophilic prepolymer based polyurethane foams, methods for producing the same and use thereof in antiseptic wound dressings |
| KR20160126201A (en) * | 2015-04-23 | 2016-11-02 | 주식회사 대웅제약 | Process for preparing polyurethane foam dressing comprising anti-inflammatory agent |
| CN108355162B (en) * | 2018-05-14 | 2021-07-23 | 江西省科学院应用化学研究所 | Medical dressing of antibiotic hydrophilic polyurethane foam |
| CN109568636A (en) * | 2018-12-11 | 2019-04-05 | 长春安旨科技有限公司 | A kind of multifunctional polyurethane foam dressing and preparation method thereof |
| CN112266455B (en) * | 2020-09-29 | 2022-07-12 | 万华化学集团股份有限公司 | Modified high blood-absorption polyurethane sponge, preparation method and application thereof |
| CN112266454B (en) * | 2020-11-06 | 2022-01-28 | 江苏海洋大学 | Application of hydroxyl-terminated polymer in preparation of multifunctional polyurethane soft foam dressing |
| CN112646162B (en) * | 2020-12-14 | 2022-10-04 | 山东一诺威新材料有限公司 | Preparation method of polyether chain extender for waterborne polyurethane |
| CN115779129A (en) * | 2022-11-18 | 2023-03-14 | 哈尔滨生材新材料科技发展有限公司 | High-adsorbability porous structure polyurethane dressing |
-
2023
- 2023-04-28 CN CN202310473192.7A patent/CN116178670B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2158924A1 (en) * | 2008-08-27 | 2010-03-03 | Bayer MaterialScience AG | Method for producing formed polyurethane foam wound dressing |
| CN105153393A (en) * | 2015-08-04 | 2015-12-16 | 李明莹 | Hydrophilic and biological safe polymer foam, and preparation method and application of polymer foam |
| CN105440240A (en) * | 2015-12-04 | 2016-03-30 | 上海华峰材料科技研究院（有限合伙） | Continuous production method for preparing waterborne polyurethane ionomer and dispersoid of waterborne polyurethane ionomer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116178670A (en) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60038404T2 (en) | Cold-cured molded flexible polyurethane foam and process for its preparation | |
| DE2265354C2 (en) | Process for the manufacture of a cell stabilizer | |
| CN110105525B (en) | NDI-based polyurethane microporous elastomer resistant to damp-heat aging and preparation method thereof | |
| CN116178670B (en) | Polyurethane composite material for medical dressing foam and preparation method thereof | |
| CN107189746B (en) | Reactive polyurethane medical adhesive and preparation method thereof | |
| CN111363186B (en) | Polyurethane foam material, preparation method thereof and application thereof in wound dressing | |
| CN113549189A (en) | Polyurethane slow-resilience sponge and preparation method thereof | |
| CN111040108B (en) | Preparation method of coarse-pore nontoxic cleaning sponge material | |
| CN112940239A (en) | Preparation method of hybrid block polyether polyol | |
| KR20120103623A (en) | Improved elastomeric compositions | |
| CN110845696A (en) | Waterborne polyurethane resin and preparation method thereof | |
| CN115197395A (en) | Aqueous polyurethane for impregnation of microfiber leather and preparation method and application thereof | |
| CN110283308A (en) | A kind of preparation method of the stabilizer for synthesis of polymer polyalcohol | |
| JPH04185627A (en) | Flexible polyurethane form | |
| CN117384345B (en) | Water-absorbing expansion polyurethane foam and preparation method thereof | |
| CN115232258A (en) | Polyester ether-based polymer polyol and preparation method and application thereof | |
| CN114106280A (en) | Aliphatic polyurethane resin and preparation method and application thereof | |
| US5288921A (en) | Process for reducing unsaturation on polyols | |
| CN113527616A (en) | Polyurethane common soft foam and preparation method thereof | |
| CN110922572A (en) | Preparation method of polyester polyol for polyurethane flexible foam, polyurethane flexible foam prepared by preparation method and preparation method of polyurethane flexible foam | |
| WO2020248765A1 (en) | Method for preparing cellulose-based rigid polyurethane foam | |
| CN115572385B (en) | Preparation method of plant-based polyether polyol | |
| CN117430803B (en) | Salicylic acid modified sinapyl alcohol polyether polyol and preparation method thereof | |
| CN113861370B (en) | Polyurethane composite material for cosmetic cotton and preparation method thereof | |
| CN111021089B (en) | Super-fiber bass full-water filling method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |